Michael Joseph Behna, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 3309 S 750 W, Russiaville, IN 46979 Phone: 765-883-2273 |
Kristen L Fox, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3309 S 750 W, Russiaville, IN 46979 Phone: 765-765-8832 |
Lisa Montgomery, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3309 S 750 W, Russiaville, IN 46979 Phone: 765-883-2273 |
Natasha Renee Theiring, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 3309 S 750 W, Russiaville, IN 46979 Phone: 765-883-2273 Fax: 765-883-5168 |
James Cole, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 101 S. Liberty Street, Russiaville, IN 46979 Phone: 765-883-2273 Fax: 765-883-5168 |
News Archive
Hospitals and health systems preparing for and treating patients with Ebola Virus Disease (EVD) in the fall of 2015 faced unexpected challenges for ensuring safety of staff, patients and the community. The experiences are detailed in two studies published online in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.
The Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al launches B2Discovery, a new research funding model that brings together the private sector and the biomedical research community to help accelerate the discovery of new anti-cancer therapeutics. Inspired by B2ten, which contributed to the success of several Canadian athletes at the Vancouver Winter Olympics, B2Discovery's mission is to partner entrepreneurs with IRIC's cancer investigators to finance novel and promising research projects not currently funded by public granting agencies.
By analyzing throat and nose swabs from patients in Southern California, researchers detected a new SARS-CoV-2 strain with mutations in the spike protein. This major finding may explain a surge in the number of cases in the region.
A group of top scientists in Britain have warned patients to be wary of "extravagant" claims made for "unorthodox" stem cell treatments offered abroad and that some stem cell treatments could be killers.
Inhibitex, Inc. today reported the completion of its previously announced $23 million private placement of common stock and warrants. Investors in the private placement purchased units, each consisting of one share of common stock and a warrant to purchase .45 of a share of common stock, at a purchase price of $1.28 per unit, which is equal to the consolidated closing bid price of the common stock as reported on the NASDAQ Capital Market for October 22, 2009, plus $0.06.
› Verified 9 days ago